dr. moore on safety profile of mirvetuximab soravtansine in ovarian cancer
Published 4 years ago • 127 plays • Length 1:49Download video MP4
Download video MP3
Similar videos
-
2:28
dr. moore on the role of mirvetuximab soravtansine in ovarian cancer
-
1:15
dr. o’malley on the safety profile of mirvetuximab in ovarian cancer
-
2:15
dr. moore on early-phase data with mirvetuximab soravtansine in ovarian cancer
-
1:41
dr. moore on benefit of mirvetuximab soravtansine in patients with ovarian cancer
-
1:59
dr. gilbert on the safety profile of mirvetuximab soravtansine/bevacizumab in ovarian cancer
-
1:59
dr. english on mirvetuximab soravtansine in ovarian cancer
-
0:54
dr. moore on the prevalence of ovarian cancer
-
1:13
dr. o’malley on the activity of mirvetuximab soravtansine in ovarian cancer
-
1:50
dr. moore on results of the forward i/gog 3011 trial in ovarian cancer
-
1:50
an overview of a study exploring mirvetuximab soravtansine in ovarian cancer
-
2:09
dr. moore on the nova trial for ovarian cancer
-
1:34
dr. moore on challenges with immunotherapy in ovarian cancer
-
1:47
mirvetuximab soravtansine remains well tolerated in platinum-resistant ovarian cancer
-
1:16
dr. moore discusses combinations in ovarian cancer
-
0:58
dr. o’malley on the utility of mirvetuximab in ovarian cancer
-
2:03
dr. moore on treatment for patients with ovarian cancer who develop resistance to parp inhibitors
-
8:03
parp inhibitors in ovarian cancer: safety profile
-
0:26
copy of dr. english on mirvetuximab soravtansine in ovarian cancer
-
1:30
dr. english on an investigational antibody-drug conjugate in ovarian cancer